Shanghai Junshi Biosciences Co., Ltd. in 1 story
The narratives 1877.HK currently appears in, with its side and exposure in each.
Bull side
1 story- China Becomes Pharma's Global R&D Engine
1877.HK in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
The US approval of China-developed toripalimab provides tangible regulatory validation for its broader innovative oncology pipeline.
Bear side
0 storiesNo bear-side stories for 1877.HK yet.